Crucell product portfolio:

• Quinvaxem^®
• Hepavax-Gene^®
• MoRu-Viraten^® 
• Inflexal^® V
• Epaxal^®
• Vivotif^®
• Dukoral^®

• We combine the use of established and new technologies such as PER.C6^®, STAR^®, MAbstract^®, AdVac^® and our virosomal technology, as well as other proprietary technology platforms.

• We believe our unique PER.C6^® human cell line technology is well suited for the development and industrial-scale manufacturing of a wide range of biopharmaceuticals, such as vaccines and proteins.

• Product pipeline programs comprise vaccines against yellow fever, influenza, Ebola, malaria and tuberculosis, and protein products such as the rabies antibodies mix and blood coagulation factors. 

• Our locations:
  • Corporate headquarters: Leiden, The Netherlands
  • R&D facilities: Netherlands, Switzerland, Sweden and Korea
  • Manufacturing facilities: Switzerland, Sweden, Korea, Spain
  • Sales and marketing: Argentina, China, Indonesia, Italy, Korea, Netherlands, Norway, Spain, Portugal, Sweden, Switzerland, United States, Vietnam

• Stock exchange listings: NASDAQ (CRXL), Euronext (CRXL), SWX Swiss Exchange (CRX)